Cover Image

Expression of nectin-4 in papillary renal cell carcinoma

Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf...

Full description

Saved in:
Bibliographic Details
Main Authors: Zschäbitz, Stefanie (Author) , Mikuteit, Marie (Author) , Stöhr, Christine (Author) , Herrmann, Edwin (Author) , Polifka, Iris (Author) , Agaimy, Abbas (Author) , Trojan, Lutz (Author) , Ströbel, Philipp (Author) , Becker, Frank (Author) , Wülfing, Christian (Author) , Barth, Peter (Author) , Stöckle, Michael (Author) , Staehler, Michael (Author) , Stief, Christian (Author) , Haferkamp, Axel (Author) , Hohenfellner, Markus (Author) , Duensing, Stefan (Author) , Macher-Göppinger, Stephan (Author) , Wullich, Bernd (Author) , Noldus, Joachim (Author) , Brenner, Walburgis (Author) , Roos, Frederik C. (Author) , Walter, Bernhard (Author) , Otto, Wolfgang (Author) , Burger, Maximilian (Author) , Schrader, Andres Jan (Author) , Hartmann, Arndt (Author) , Erlmeier, Franziska (Author) , Steffens, Sandra (Author)
Format: Article (Journal)
Language:English
Published: 22 September 2022
In: Discover oncology
Year: 2022, Volume: 13
ISSN:2730-6011
DOI:10.1007/s12672-022-00558-2
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12672-022-00558-2
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s12672-022-00558-2
Get full text
Author Notes:Stefanie Zschäbitz, Marie Mikuteit, Christine Stöhr, Edwin Herrmann, Iris Polifka, Abbas Agaimy, Lutz Trojan, Philipp Ströbel, Frank Becker, Christian Wülfing, Peter Barth, Michael Stöckle, Michael Staehler, Christian Stief, Axel Haferkamp, Markus Hohenfellner, Stefan Duensing, Stephan Macher-Göppinger, Bernd Wullich, Joachim Noldus, Walburgis Brenner, Frederik C. Roos, Bernhard Walter, Wolfgang Otto, Maximilian Burger, Andres Jan Schrader, Arndt Hartmann, Franziska Erlmeier, Sandra Steffens
Description
Summary:Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens.
Item Description:Gesehen am 08.11.2022
Physical Description:Online Resource
ISSN:2730-6011
DOI:10.1007/s12672-022-00558-2

Similar Items